| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 1.6K | 78.2% | 103.9% |
| Total Income | 1.6K | 79.7% | 105.9% |
| Expenditure | 1.3K | 108.8% | 141.7% |
| PBT | 273.21 | 6.6% | 19.2% |
| Net Profit | 213.37 | 10.1% | 18.1% |
| OPM | 27.73% | 5.27pp | 7.06pp |
| NPM | 13.20% | 8.34pp | 9.83pp |
| EPS | 12.98 | 12.4% | 20.1% |
Strong Q2, TruBridge integration on track, multi-year upside ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Q2 hit guidance targets. FY30 EBITDA target reaffirmed (no miss). Legacy IKS growth aspiration 12%+ maintained. TruBridge margin roadmap deferred.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q2 delivered on targets with EBITDA and margin discipline intact post-TruBridge acquisition. TruBridge integration progressing well, and long-term strategic vision (FY30 INR 3,000 Cr EBITDA via system of action) is credible. Key risk: FY28-29 modeled as integration/flat for TruBridge system of record, delaying near-term revenue acceleration; margin accretion on TruBridge remains multiyear.
₹1592.5 Cr
Revenue · +103.9% YoY₹213.4 Cr
Reported PAT · +18.1% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue INR 1,592 crores; continued strong momentum
METDelivered INR 1,592.5 Cr; 103.9% YoY growth
EBITDA 28%; healthy margins maintained post-acquisition
METOPM 27.7%; EBITDA margin close to claimed 28%
Legacy IKS growing >13% YoY in USD; strong dollar growth
METImplied $101M USD growth vs prior $101M; consistent with claim
TruBridge integration going well; on track for synergies
METMet integration milestones; 50+ TruBridge customers engaged; early synergy analysis beats expectations
Not modeling significant growth in TruBridge system of record FY28-29
METExplicit statement; cautious on near-term TruBridge revenue ramp
Earnings quality
What changed since the last call
TruBridge integration scope expanded
UpgradeNow actively rolling out system of action features (denial prevention, coding, clinical documentation) into TruBridge EHR; originally deferred. Early customer assessments beating expectations.
Patient record access expanded
UpgradeTruBridge holds 3.5-4x more patient records (millions) than the ~5M expected; strengthens AI training moat significantly.
System of record growth FY28-29 outlook
DowngradeExplicitly not modeling significant growth in TruBridge legacy EHR system of record in FY28-29; integration/consolidation year. Defers TruBridge revenue acceleration.
FY30 EBITDA target
NeutralINR 3,000 Cr EBITDA reaffirmed (unchanged from prior call). No uplift despite strong Q2 and expanded synergy thesis.
The Q&A
Q&A tone: Analysts pressed on TruBridge margin path, top client concentration, and growth trajectory. Management held firm on integration-first approach, deferred granular margin guidance for FY28, but provided concrete examples on synergy mechanics (EHR rationalization, RCM cost leverage). Did not break under pressure on growth timing; stance: patience on TruBridge system of action ramp.
TruBridge margin improvement — Ruchi Mukhija, ICICI Securities
AnsweredOperating costs: technology-first, human-in-loop in financial health customer base (2/3 of TruBridge). Overhead: SG&A synergies from public company overhead removal, leadership redundancy channels, integration holistically.
Top client revenue decline — Madhuchanda Dey, MC Pro
AnsweredShort-term project from one top customer ended. Overall growth remains healthy due to new logos (White-Wilson, Evolve, UMass Memorial, MISH hospitals). Top 10 concentration has been offset by new client wins.
Organic growth expectations — Ruchi Mukhija, ICICI Securities
AnsweredYes. Historically done so consistently over 8 quarters. Bandwidth now spread across larger book; still confident will beat 12% industry growth. Pace favorable for few quarters then base effect.
Debt repayment roadmap — Chirag Kachhadiya, Motilal Oswal
Answered5-year facility loan; interest payments ~INR 10M/quarter at current rates. 18-month moratorium on principal ends; then repayment via synergies and cash generation. Current net debt INR 5,280 Cr (~INR 550M). Leverage will slide to 1.7x SOFR+1.75% as debt comes down.
TruBridge growth FY28 outlook — Vibhor Singhal, Nuvama Equities
PartialFlatish for FY28-29 in system of record business; year of consolidation and stabilization. System of action will start growing FY28 onwards; 10%-12% target in rural/community segment. Legacy IKS aspiration: better than 13% YoY.
System of intelligence timeline — Varun Gandhi, Finvenue
AnsweredDevelopment phase. Data architecture and staging built; system of intelligence layer being built task-by-task (prior auth, denial prediction, coding). One-year journey for comprehensive system of intelligence for ambulatory action system. Not yet commercialized.
TruBridge clearing house (RCM) — Dev Thacker, iThought
AnsweredYes. RCM is integral part of system of action. Can expand TAM if embedded in our offering. Incremental growth vector; not primary. Will leverage TruBridge clearing house for margin accretion in RCM offering.
AI productivity benefit pass-through — Pranaya Jain, Banyan Tree Advisors
AnsweredOutcome-based pricing model differentiates. Bulk of productivity benefit captured in bottom line; that's why industry-leading margins. Over time, AI-led model will see incremental price compression, but offset by productivity and stickiness benefits. Margins intact due to outcome model.
Guidance
FY27: Not quantified; aspiration 12%+ legacy IKS constant currency
MediumNo formal revenue guidance; aspiration only. IKS historical: 8+ quarters of >12% organic growth. TruBridge: integration year.
FY28-29: System of record flatish; system of action ramp 10%-12% target
MediumExplicit that no significant growth modeled for TruBridge legacy system in FY28-29. Rural/community TAM offers 10%-12% growth from system of action launching.
FY30: Aspiration to reach INR 3,000 Cr EBITDA (reaffirmed)
MediumTrue North target reaffirmed without dilution or net debt expansion beyond current. Implies ~15%+ CAGR from FY27 base.
Legacy IKS: Early to mid-30s EBITDA margin (maintained)
HighHistorically consistent; 34.5% this quarter. No change expected.
TruBridge: 21-22% adjusted EBITDA by end of integration (2-3 year horizon)
MediumCurrently ~17.5% adjusted (82 days). Targets cost leverage, SG&A synergies. 'It's a journey,' mgmt said; no granular Q targets.
Combined company: Back to early-to-mid-30s by FY30 (implied)
LowNot stated explicitly; inferred from INR 3,000 Cr EBITDA target. Will depend on TruBridge margin ramp.
Not quantified; AI/system of action development ongoing
LowMentioned building system of intelligence layer, Project Endeavor (rural OS). No capex budget disclosed.
Risks the call surfaced
TruBridge margin accretion
MediumManagement targets 21-22% adjusted EBITDA for TruBridge; currently 17.5%. Cost optimization roadmap (operating costs, SG&A synergies) is broad but vague on timing and quantum.
Top client concentration & revenue lumpiness
MediumTop client revenue dropped INR 480 Cr (Q1) to INR 432 Cr (Q2); short-term project loss from one top customer. Creates quarter-to-quarter volatility.
TruBridge system of record growth delay
HighManagement explicitly not modeling significant growth in TruBridge legacy EHR (system of record) for FY28-29; integration/consolidation phase. System of action ramp (10%-12% target) deferred to FY28 onwards.
System of intelligence commercialization timeline
MediumSystem of intelligence layer (AI-native platform) is still in development; timeline 1 year. Features (denial prediction, coding, clinical documentation) building incrementally. Commercialization deferred; dependency on flawless execution.
Integration complexity & execution risk
MediumMerging two large organizations (IKS legacy + TruBridge EHR + TruBridge RCM) across system of record and system of action. Three top TruBridge executives now in IKS leadership. Cultural shift from acquisition mindset (TruBridge acquired 'lifestyle company') to execution-oriented.
Management
Score 7/10. Clear and structured. CEO provided multi-dimensional integration update (people, culture, synergies, AI roadmap). CFO drilled granular numbers. Candid on challenges (TruBridge margin timing, system of record flatness FY28-29). Track record: met Q2 targets (INR 1,592 Cr revenue, 28% EBITDA). Reaffirmed FY30 INR 3,000 Cr target (not missed). Prior guidance on 12%+ legacy IKS growth aspiration maintained. No formal FY27 revenue guidance given = no miss possible.
1 · Q3 FY27
ESOP grant disclosure and impact modeling on adjusted EBITDA
2 · Q4 FY27
First three AI system of action features live in TruBridge EHR for customers
3 · Q1 FY28
Project Endeavor (rural market operating system) launch; system of intelligence layer live
Key risk: FY28-29 modeled as integration/flat for TruBridge system of record, delaying near-term revenue acceleration; margin accretion on TruBridge remains multiyear.
Strong Quarter, Cautious Management: The TruBridge Ramp is Deferred
Q2 revenue and margins hit targets, but management explicitly parked TruBridge system of record growth in FY28–29 and reaffirmed the FY30 EBITDA target without uplift despite 'early synergies beating expectations.' The tension defines the quarter.
₹213 Cr
+18% YoY
₹60 Cr
one-time headwind
~₹273 Cr
17% net margin
Inventurus landed exactly where guidance pointed: ₹1,593 Cr revenue, 28% EBITDA margin, and a delivered TruBridge acquisition that is integrating on schedule. On the surface, it's a clean beat. But the real story lives in what management didn't do — they reaffirmed the FY30 EBITDA target of INR 3,000 Cr despite a Q2 that they described as showing 'early synergies beating expectations.' That gap between upside surprise and unchanged guidance is the tension that defines the quarter.
The reported quarter masks integration drag
Reported PAT of ₹213 Cr grew 18% YoY, but that headline is dragged down by ₹25 Cr in one-time integration costs and ESOP dilution (~4% of shares) that will weigh on adjusted metrics going forward. Backing those out, adjusted PAT is approximately ₹273 Cr — a 17% net margin — which reconciles to the strong underlying operational beat. The reconciliation matters because management will report similar integration costs through FY28, and investors need to strip them out to see the organic profit trajectory.
Revenue INR 1,592 Cr; strong momentum
Delivered ₹1,592.5 Cr; +103.9% YoY, +78% QoQ
Supported
EBITDA 28%; margins maintained post-acquisition
OPM 27.7%; adjusted EBITDA ₹442 Cr
Supported
Legacy IKS >13% YoY in USD; beats 12% industry growth
Implied USD 101M quarterly (~INR 855M annualized); consistent with claim
Supported
TruBridge integration on track; early synergies beat expectations
50+ customers engaged, 75 execs aligned, no material revenue synergies yet
Supported (but early phase)
Not modeling significant TruBridge system of record growth FY28–29
Explicit deferral; integration-focused fiscal '28–29
Supported (cautious signal)
What changed on this call
Three material shifts from prior: First, TruBridge system of action features are now live in FY28, not deferred. Three denial prevention, clinical coding, and documentation AI modules go into the EHR by Q1 FY28, supported by a patient record moat that turned out to be 3.5–4× larger than expected — millions of records, not the ~5M initially modeled. Second, the company explicitly parked TruBridge legacy EHR (system of record) growth in FY28–29, downgrading the near-term ramp expectation from earlier calls. FY28–29 is now 'integration and stabilization,' with system of action driving the 10–12% growth target only from FY28 onwards in the rural market segment. Third, and most credibility-damaging: the FY30 EBITDA target of INR 3,000 Cr was reaffirmed, not raised, despite synergy surprises. That move signals management sees meaningful execution risk ahead, or the upside is smaller than the call's tone suggested.
Q2 revenue and margin beat targets; integration on pace (no major misses)
Legacy IKS >13% YoY organic growth (beats 12% industry aspiration)
EBITDA margin discipline intact (28%) despite ₹25 Cr integration costs
Patient data moat (3.5–4 million records, 3.5–4× expected) strengthens AI training advantage
Outcome-based pricing model insulates margin from AI productivity tail winds
TruBridge system of record explicitly flat FY28–29 (three-quarter revenue deferral vs. bull expectations)
Top client lumpiness (₹48 Cr Q1–Q2 project loss); near-term volatility risk
TruBridge margin accretion (21–22% target) is vague; no quarterly milestones
FY30 EBITDA target reaffirmed, not raised, despite 'early synergies beat expectations'
System of intelligence still in development (1-year timeline); commercialization deferred
TruBridge system of record growth deferred; FY28–29 integration extends revenue ramp
HighLargest execution risk on the call. Management explicitly not modeling significant growth in TruBridge EHR for two years signals either deep integration complexity or margin accretion is slower than assumed. If system of action launch slips past Q1 FY28, revenue acceleration delays further.
TruBridge margin accretion (21–22% target) vague; 'it's a journey'
MediumCurrently ~17.5% adjusted; gap of 3–5 percentage points to target. No quarterly milestones shared. If cost leverage or SG&A synergies underperform, margins stay stuck, killing the FY30 EBITDA math.
Top client concentration and project lumpiness
Medium₹480 Cr (Q1) → ₹432 Cr (Q2) swing driven by one customer project loss. Creates quarter-to-quarter volatility and masks underlying organic run-rate. New logos (White-Wilson, Evolve, UMass) offset for now, but concentration risk remains.
System of intelligence commercialization timeline (1-year dev estimate)
MediumStill in development phase; not yet commercialized. If build slips past 12 months or feature adoption is slower than expected, near-term revenue contribution to system of action growth is diminished.
FY30 EBITDA target reaffirmed, not raised, despite upside surprises
MediumCredibility flag. If early synergies truly beat expectations, why not raise the target? Suggests management sees execution risk or is being conservatively defensive. Market may reprrice expectations down.
How the street is positioned
The stock is trading at ₹1,665.5, down 24% from its all-time high of ₹2,189 and +32% off its 52-week low of ₹1,262. It sits below its 20-day and 50-day moving averages (₹1,693.64 and ₹1,740.38, respectively) but above the 200-day average (₹1,659.37), suggesting a modest downtrend that is not yet in deep oversold territory — RSI of 43.8 is neutral, and volume is normal. FII ownership has trimmed slightly (−0.19 percentage points QoQ to 8.00%), while DII has accumulated (+1.1 pp to 7.50%). Promoter stake remains locked at 63.72%. Recent bulk deals show Kedaara Capital buying 2 lakh shares at ₹1,654.90 (institutional accumulation), while Scott Hayworth sold an equal position at the same price (rebalance, not insider concern). The price action and flows suggest the market is digesting the Q2 beat but remains cautious on the FY28–29 guidance deferral — the 24% drawdown from the ATH is fair value for a stock that promises 15%+ CAGR but requires two years of integration before proof emerges.
1 · Q3 FY27 (Dec 2026): ESOP impact and adjusted EBITDA modeling
ESOP grant (~4% dilution) gets disclosed. Watch how adjusted EBITDA is impacted and whether management provides framework for stripping it out. If adjusted metrics deteriorate faster than expected, TruBridge margin ramp credibility weakens.
2 · Q4 FY27 (Mar 2027): System of action features live in TruBridge EHR
First three denial prevention, coding, and clinical documentation AI modules go live. Customer traction and early adoption metrics are the proof point for the 10–12% rural market TAM growth thesis. Slippage here ripples into FY28 guidance.
3 · Q1 FY28 (Jun 2027): Project Endeavor rural market OS and system of intelligence launch
Rural operating system for community hospitals and Project Endeavor go live. System of intelligence layer becomes commercially available. These are the catalysts that justify the FY30 INR 3,000 Cr EBITDA target. Execute cleanly or miss, and the market reprices the whole thesis.
Inventurus delivered a clean Q2 — revenue and margins on target, integration on schedule, patient data moat larger than expected. But management's explicit caution on FY28–29 TruBridge growth and refusal to uplift the FY30 EBITDA target despite self-described upside surprises is the real story. This is steady execution in the early innings of a multi-year integration, not a step-change. The stock is fairly valued at ₹1,665.5 given the 'show me' story ahead.
The verdict: Hold. Buy if and when Q4 FY27 system of action launch and Q1 FY28 Project Endeavor proof points de-risk the execution path. The number to track from here is TruBridge margin progression — each quarter watch whether adjusted EBITDA margin is trending toward the 21–22% target or staying flat near 17.5%. If it slips below 19% by mid-FY28, the margin accretion thesis fails, and the FY30 EBITDA target becomes unachievable. That's your downgrade trigger.